Research programme: antibacterials - Oragenics

Drug Profile

Research programme: antibacterials - Oragenics

Alternative Names: Lantibiotics; MU 1140-S; MU-1140; MU1140 analogs - Oragenics; Mutacin 1140; OG 253; OG 716

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Florida
  • Developer Intrexon Corporation; Oragenics Inc
  • Class Bacteriocins; Cyclic peptides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Clostridium infections
  • No development reported Bacterial infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA (IV, Infusion)
  • 27 Feb 2017 Oragenics has a patent pending for lantibiotic MU 1140 and its homologues in USA (Oragenics 10-K, February 2017)
  • 27 Feb 2017 Oragenics has patent protection for lantibiotic MU 1140 and its homologues in USA (Oragenics 10-K, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top